CompletedPhase 1NCT04377672

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Johns Hopkins University
Principal Investigator
Sanjay K Jain, MD
Johns Hopkins University
Intervention
Anti-SARS-CoV-2 Human Convalescent Plasma(biological)
Enrollment
14 target
Eligibility
18 years · All sexes
Timeline
20202021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04377672 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials